As we enter into the second year since the outbreak of the COVID-19 pandemic, the bio/pharmaceutical industry is adjusting its business practices and priorities as the next phase of response to this global emergency unfolds.

The pandemic highlighted a variety of issues related to the biopharmaceutical supply chain and heightened demands for COVID-19 treatments, which pharma companies have had to balance with a heightened workload.

In the latest roundtable discussion with BioPharm International, our contract manufacturing lead Tom Wilson spoke alongside other industry leaders about these supply chain challenges and how we were able to change our business processes and develop best practices to ensure effective remote partnerships.